
WEEKLY EPIDEMIOLOGY BULLETIN NATIONAL EPIDEMIOLOGY UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

Weekly Spotlight

Cardiovascular diseases



Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels. They include:

• coronary heart disease – a disease of the blood vessels supplying the heart muscle;

• cerebrovascular disease – a disease of the blood vessels supplying the brain;

• peripheral arterial disease – a upplying the arms and legs;

disease of blood vessels supplying the arms and legs;

- rheumatic heart disease damage to the heart muscle and heart valves from rheumatic fever, caused by streptococcal bacteria;
- congenital heart disease birth defects that affect the normal development and functioning of the heart caused by malformations of the heart structure from birth; and
- deep vein thrombosis and pulmonary embolism blood clots in the leg veins, which can dislodge and move to the heart and lungs.

Heart attacks and strokes are usually acute events and are mainly caused by a blockage that prevents blood from flowing to the heart or brain. The most common reason for this is a build-up of fatty deposits on the inner walls of the blood vessels that supply the heart or brain. Strokes can be caused by bleeding from a blood vessel in the brain or from blood clots.

Symptoms of heart attacks and strokes

Often, there are no symptoms of the underlying disease of the blood vessels. A heart attack or stroke may be the first sign of underlying disease. Symptoms of a heart attack include: pain or discomfort in the centre of the chest; and/or pain or discomfort in the arms, the left shoulder, elbows, jaw, or back.

In addition the person may experience difficulty in breathing or shortness of breath; nausea or vomiting; light-headedness or faintness; a cold sweat; and turning pale. Women are more likely than men to have shortness of breath, nausea, vomiting, and back or jaw pain. The most common symptom of a stroke is sudden weakness of the face, arm, or leg, most often on one side of the body. Other symptoms include sudden onset of:

- numbness of the face, arm, or leg, especially on one side of the body;
- confusion, difficulty speaking or understanding speech;
- difficulty seeing with one or both eyes;
- difficulty walking, dizziness and/or loss of balance or coordination;
- severe headache with no known cause; and/or
- fainting or unconsciousness.

People experiencing these symptoms should seek medical care immediately.

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

EPI WEEK 37




- Syndromic Surveillance
- Accidents
- Violence

Pages 2-4

Page 5

Class 1 Notifiable Events





COVID-19

Page 6



Influenza

Page 7

Page 8

Dengue Fever

AR

g or road

re-search



Page 9

Sentinel Surveillance in Iamaica



Table showcasing the **Timeliness of Weekly Sentinel Surveillance Parish Reports for the Four** Most Recent Epidemiological Weeks -34 to 37 of 2023

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. **Reports submitted after 3** p.m. are considered late.

KEY:

Yellow- late submission on Tuesday Red - late submission after Tuesday

A syndromic surveillance system is good for early detection of and response to public health events.

Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.

Epi week	Kingston and Saint Andrew	Saint Thomas	Saint Catherine	Portland	Saint Mary	Saint Ann	Trelawny 23	Saint James	Hanover	Westmoreland	Saint Elizabeth	Manchester	Clarendon
34	On	On	On	On	On	On	On	On	On	On	On	On	Late
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	(W)
35	On	On	On	On	On	On	On	On	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
36	On	On	On	On	On	On	On	On	On	On	On	On	Late
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	(T)
37	On	On	On	On	On	On	On	Late	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	(T)	Time	Time	Time	Time	Time

REPORTS FOR SYNDROMIC SURVEILLANCE

UNDIFFERENTIATED FEVER

Temperature of >38°C /100.4°*F* (or recent history of fever) with or without an oby inf

1400

1200

S




ovious diagnosis or focus of fection.	1000 800 600 400 200 0 1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 Epidemiologic week 2023 <5 2023 >5 Epidemic Threshold <5 Epidemic Threshold ≥5
2 NOTIFICATIONS- All clinical sites	INVESTIGATION REPORTS- Detailed Follow up for all Class One Events Up for all Class One Events HOSPITAL ACTIVE SURVEILLANCE- 30 sites. Actively pursued

Weekly Visits to Sentinel Sites for Undifferentiated Fever All ages: Jamaica, Weekly Threshold vs Cases 2023

September 29 , 2023

FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



Alert Threshold

Weekly visits to Sentinel Sites for Fever and Haemorrhagic 2022 and

2023 vs Weekly Threshold; Jamaica

- Epidemic Threshold

ISSN 0799-3927



FEVER AND HAEMORRHAGIC

Temperature of $>38^{\circ}C$ /100.4°F (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.



FEVER AND JAUNDICE

Temperature of $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.

The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.



3 NOTIFICATIONS-All clinical sites

INVESTIGATION REPORTS- Detailed Follow up for all Class One Events

2022

8

7

6

5

4

3

2

1


Number of visits


2023


HOSPITAL
ACTIVE
SURVEILL
30 sites Activ

ACTIVE SURVEILLANCE-30 sites. Actively pursued









All clinical sites

1S-

INVESTIGATION REPORTS- Detailed Follow up for all Class One Events

ACTIVE SURVEILLANCE-30 sites. Actively pursued





ISSN 0799-3927

CLASS ONE NOTIFIABLE EVENTS

Comments

			Confirm	ed YTD ^{α}	AFP Field Guides from		
CLASS 1 EVENTS			CURRENT YEAR 2023	PREVIOUS YEAR 2022	WHO indicate that for an effective surveillance system, detection rates for		
	Accidental Po	bisoning	240 ^β	159 ^β	AFP should be 1/100,000		
Ę	Cholera		0	0	population under 15 years		
NATIONAL /INTERNATIONAL INTEREST	Dengue Hem	orrhagic Fever ⁷	See Dengue page below	See Dengue page below	old (6 to 7) cases annually.		
	COVID-19 (\$	SARS-CoV-2)	3589	54318	Pertussis-like syndrome		
	Hansen's Dis	ease (Leprosy)	0	0	and Tetanus are clinically		
L /INTERN INTEREST	Hepatitis B		46	26	confirmed classifications.		
AL /	Hepatitis C		24	2	γ Dengue Hemorrhagic		
/NO	HIV/AIDS		N/A	N/A	Fever data include Dengue		
ATI	Malaria (Imp	ported)	3	2	related deaths;		
Z	Meningitis		23	15	$^{\delta}$ Figures include all deaths		
	Monkeypox		3	14	associated with pregnancy		
EXOTIC/ UNUSUAL	Plague		0	0	reported for the period.		
TY/	Meningococc	al Meningitis	0	0	^ε CHIKV IgM positive		
H IGH RBIDI RTALI	Neonatal Teta	anus	0	0	cases ^θ Zika PCR positive cases		
H IGH MORBIDITY/ MORTALITY	Typhoid Feve	er	0	0	β Updates made to prior		
M(Meningitis H	/Flu	0	0	weeks.		
	AFP/Polio		0	0	$^{\alpha}$ Figures are cumulative		
	Congenital R	ubella Syndrome	0	0	totals for all		
	Congenital S	yphilis	0	0	epidemiological weeks year to date.		
MES	Fever and Rash	Measles	0	0			
RAM		Rubella	0	0			
SOG	Maternal Dea	ιths ^δ	36	57			
L PF	Ophthalmia N	Neonatorum	98	48			
SPECIAL PROGRAMI	Pertussis-like	syndrome	0	0			
	Rheumatic Fe	ever	0	0			
	Tetanus		0	2			
	Tuberculosis		30	25			
	Yellow Fever		0	0			
	Chikungunya	3	0	0			
Zika Virus ^θ			0	0	NA- Not Available		

NOTIFICATIONS-5 All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





September 29,	2023		ISSN 0799-3927					
			D-19 Surveillance Update					
		Ma	rch 10, 2020 – EW 37, 2023					
CASES	EW 37	Total	Classification of Confirmed COVID-19 Cases by Date of Ons of Symptoms, Jamaica (156,510 cases)					
Confirmed	52	156510	2000					
Females	29	90221	1500 0					
Males	23	66286	No. of 1-Mar-20 1-Mar-20 1-Jul-20 1-Jul-20 1-Jul-21 1-Jul-21 1-Jul-21 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-22 1-Jul-23					
Age Range	17 days old to 94 years	1 day to 108 years	Date of Onset of Symptoms					
* 3 positive cases ha * PCR or Antigen test			Contact of a Confirmed Case Import Related Imported Contact of a Confirmed Case Not Epi Linked Under Investigation Workplace Cluster					
COVID-19 Outc								
Outcomes	EW 37	Total	3113 COVID-19 Related Deaths since March 1, 2021 – YTD					
ACTIVE *2 weeks*		107	Vaccination Status among COVID-19 Deaths					
DIED – COVID Related	0	3675	Fully Vaccinated (82/3113) 3%					
Died - NON COVID	0	337						
Died - Under Investigation	0	270						
Recovered and discharged	3	103198	Unvacccinated (2992/3113) 96%					
Repatriated Total	0	93 156510						
*Vaccination program	nme March 2021 – Y	1						
* Total as at current	Epi week		Fully Vaccinated Partially Vaccinated Unvacccinated					
COVID-19 Pari	sh Distributio	h and Global						
	ID-19 Virus Structure	2	COVID19 Cases by Parish Total Cases Legend					
SARS-CoV-2	Julie	Spike (S)	St. Amil Tabley B. Amil Folder Confirmed COVIDING 8528 - 17579 4645 17979 5214 11549 e tabley e tabley e tabley e tabley 28161 - 41747					
	3020	Nucleocapsid (N)	8817 4972 Parame					
8 8 8 9	JOSOF	Membrane (M)	Namoskie 6614 28160 4170 4028					
8.8.6s	and all have	Envelope (E)	6614 8927 7871 28160 41127 5987					
		RNA viral genome	B. Baser Sector S. Cours					
COVID-19 WHC) Global Statisticts E	W34-EW37	Curron					
Epi Week	Confirmed	Deaths	EW 37 Cases Legend					
34	Cases 336, 282	382	2 8 1 3 0 3 Image: Sept. 16.2023 4.8 9 9.12 1.2 Paralese 1.2 Paralese					
35	228, 774	1141	Reinsard Date Repard September 29, 2023					
36	82,790	257						
37	37,316	170	2 Bizer Modeser S. Carrer S. Carrer					
Total (4weeks)	685,162	1950						
6 NOTIFIC All clinic sites	CATIONS-		GATION - Detailed Follow ass One Events HOSPITAL ACTIVE SURVEILLANCE- 30 sites. Actively pursued SURVEILLANCE-					

30 sites. Actively pursued


September 29, 2023

NATIONAL SURVEILLANCE UNIT **INFLUENZA REPORT**

ISSN 0799-3927


 $\overline{EW37}$

September 10 - September 16, 2023 Epidemiological Week 37




Epi Week Summary

During EW 37, four(4) SARI admissions were reported.



Respiratory Illness (SARI 2023) (compared with 2011-2021)




Caribbean Update EW 37

Caribbean: Influenza activity continues to exhibit a declining trend over the past 4 EWs. During this period, the predominant influenza viruses have been B/Victoria, with lesser circulation of influenza A, primarily A(H1N1)pdm09. RSV activity has remained low. SARS-CoV-2 activity shows an increasing trend with intermediate to high levels of circulation. ILI and SARI cases have demonstrated a declining trend over the past 4 EWs.

Distribution of Influenza and Other Respiratory Viruses Under

Surveillance by EW, Jamaica - 2023



Positive

NOTIFICATIONS-**INVESTIGATION**

REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

SENTINEL REPORT- 78 sites. Automatic reporting




7

All clinical

sites


ISSN 0799-3927



Suspected dengue cases for 2020, 2021, 2022 and 2023 versus monthly mean, alert, and epidemic thresholds (2007-2022)

Points to note:

- *Figure as at September 16, 2023
- Only PCR positive dengue cases are reported as confirmed.
- IgM positive cases are classified as presumed dengue.



8 NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





RESEARCH PAPER

Abstract

NHRC-21-03 The Neurodevelopmental Outcomes of Congenital Zika Syndrome in Jamaican Children

R Melbourne-Chambers^{1,5}, P Palmer⁵, Y Brown², T James-Powell^{3,5}, J Tapper⁴, 5, L Mowatt^{1,5}, I Siqueira⁶, C Thorne⁷, ZIKAction Paediatric Registry Study Group, CDC Christie^{1.5}

¹University Hospital of the West Indies, ²Victoria Jubilee Hospital, ³Spanish Town Hospital, ⁴Bustamante Hospital for Children, ⁵The University of the West Indies, ⁶Instituto Gonçalo Moniz-Fiocruz, Brazil, ⁷UCL Great Ormond Street Institute of Child Health, University College London

This project has received funding from the European Union's Horizon 2020 research and Innovation Program under grant agreement No. 734857.

Introduction: As part of a multicentre registry, this study aimed to characterize the clinical, radiological, neurodevelopmental and laboratory features of children antenatally exposed to ZIKV and/or presenting with suspected congenital zika syndrome (CZS) in Jamaica.

Methods: Retrospective study of children potentially exposed to Zika antenatally and attended clinics at/ admitted to either of four public hospitals in the Kingston and St Andrew (KSA) region and St. Catherine, Jamaica who met >/= 1 inclusion criteria: 1. Microcephalic at birth, 2. Features of CZS 3. Exposed to Zika in utero. Data: maternal demography, antenatal, labour, delivery history, newborn anthropometry, results of hearing, vision screening, neurodevelopmental assessment, laboratory, radiologic investigations were extracted from hospital records. Descriptive and Chi square analyses were performed. Ethical approval was obtained.

Results: 55 participants; 34 (61.8%) female; 4 (7.3%) born premature; 4 (7.2%) neonates -lab confirmed Zika; 6 (10.9%) mothers - lab confirmed Zika, 6 (10.9%) mothers Zika symptomatic (no lab confirmation); 31 (56.4%) congenital microcephaly, 14 (25.9%) severe; 20 (36.3%) craniofacial disproportion, 3 (5.4%) arthrogryposis. 9/34 (26.5%) abnormal ophthalmology findings; 6/12 (50.0%) abnormal hearing. 26/33 (78.8%) had abnormal neuroimaging findings. 8 (33.3%) ventriculomegaly, 7 (29.2%) cerebral/basal ganglia calcifications, 5 (20.8%) migrational abnormalities, 5 (20.8%) cortical atrophy, 3 (12.5%) cerebellar malformations. 20/36 (55.5%) had developmental delay. There was one death. Developmental delay was associated with abnormal neuroimaging (p=0.003), ophthalmology abnormalities (p=0.023) and hearing abnormalities (p=0.005) but not with head circumference (p=0.89).

Conclusions: CZS was more common in Jamaican females. Half developed developmental delay significantly associated with abnormal neuroimaging, ophthalmology and hearing.



sites

NOTIFICATIONS All clinical

The Ministry of Health and Wellness 24-26 Grenada Crescent Kingston 5, Jamaica Tele: (876) 633-7924 Email: surveillance@moh.gov.jm

INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



